Rizatriptan vs sumatriptan in the acute treatment of migraine: A placebo-controlled, dose-ranging study

Archives of Neurology

Volumn 53, Issue 11, 1996, Pages 1132-1137

  Visser, W Hester ^a,b   Terwindt, Gisela M ^a   Reines, Scott A ^b   Jiang, Kai ^b   Lines, Chris R ^b   Ferrari, Michel D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIZATRIPTAN; SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0029824318     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1996.00550110072014     Document Type: Article

References (30)

1. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - A prevalence study. J Clin Epidemiol. 1991;44:1147-1157.
2. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992;12:221-228.
3. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relations to age, income, race and other sociodemographic factors. JAMA. 1992;267:64-70.
4. Stewart WF, Lipton RB. Migraine headache: epidemiology and health care utilization. Cephalalgia. 1993;13(suppl 12):41-46.
5. Lipton RB, Stewart WF. Migraine in the United States. Neurology. 1993;43 (suppl.3):S6-S10.
6. Headache classification committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia. 1988;8(suppl 7):19-28.
7. Ashford EA, Arnold WSG, Paulsgrove L, Clements B. Ability of oral sumatriptan to improve migraine patients rating of disability. In: Olesen J, ed. Headache Classification and Epidemiology. New York, NY: Raven Press; 1994;4: 353-358.
8. Cleal AL, Blakeborough P, Gutterman DL. Ability of subcutaneous sumatriptan to improve migraine patients' rating of disability. In: Olesen J, ed. Headache Classification and Epidemiology. New York, NY: Raven Press; 1994;4:359-364.
9. Moskowitz MA. Neurogemic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci. 1992;13:307-311.
10. Humphrey PPA, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci. 1991;12:444-445.
11. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci. 1993;14:129-133.
12. 1 receptors in migraine pathophysiology and treatment. Eur J Neurol. 1995;2:5-21.
13. Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622-651.
14. Visser WH, de Vriend RHM, Jaspers NMWH, Ferrari MD. Sumatriptan in clinical practice: a two year review in 453 migraine patients. Neurology. 1996;47: 46-51.
15. Lloyd K. The clinical profile of sumatriptan: safety and tolerability. Eur Neural. 1994;34(suppl 2):40-43.
16. 1D receptor agonist MK-462. Cephalalgia. 1995;15(suppl 14): 203.
17. 10 receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with MK-462 and L-741,519. Br J Clin Pharmacol. In press.
18. Boulanger CM, Brown MJ, Desta B, et al. Comparison of the effects of 5-HT, sumatriptan and MK-462 on human isolated coronary arteries. Cephalalgia. 1995;15(suppl 14):202.
19. Ferro A, Longmore J, Hill RG, Brown MJ. A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vivo. Br J Clin Pharmacol. 1995;40:245-251.
20. 1D receptor agonist MK-462. Cephalalgia. 1995;15(suppl 14):205.
21. Cutler NR, Claghorn J, Sramek J, et al. Pilot study of MK-462 in migraine. Cephalagia. 1996;16:113-116.
22. Ferrari MD, Melamed E, Gawel M, et al. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316-321.
23. Pilgrim AJ, Blakeborough P. The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother. 1994;5:295-310.
24. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrence. Cephalalgia. 1994; 14:330-338.
25. 10 receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled dose-range finding study. Neurology. 1996;46:522-526.
26. Visser WH, Jaspers NMWH, de Vriend RHM, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia. 1996;16:264-269.
27. Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BHCH. Postmarketing study of cardiovascular adverse reactions associated with sumatriptan. BMJ. 1993;307:1185.
28. Humphrey PPA, Feniuk W, Perren MJ, et al. GR43175, a selective agonist for 5-HT1-like receptor in dog saphenous vein. Br J Pharmacol. 1988;94:1123-1132.
29. 1D subtype. Naunyn Schmiedebergs Arch Pharmacol. 1990;342:371-377.
30. 1D receptor agonists in vivo. In: Olesen J, Tfelt-Hansen P, eds. Frontiers in Headache Research: Headache Treatment, Trial Methodology, and New Drugs. New York, NY: Raven Press. In press.